Astrocyte-to-neuron conversion for Parkinson's disease treatment

Parkinson's disease (PD) is a neurodegenerative disease that is characterized by loss of dopaminergic neurons thus affects the motor system. There is no long-term effective treatment for PD yet. Recently, an article published in Nature shows that the trans-differentiation of astrocytes into dopaminergic neurons in mice model reverses the Parkinson's disease symptoms.

Qian et al. reported that inhibition of RNA-binding protein PTB results to conversion midbrain astrocytes to dopaminergic neurons which provide axons to reconstruct the nigrostriatal circuit. Moreover, re-innervation of striatum is accompanied by restoration of dopamine levels and rescue of motor deficits in PD mice model. Their findings identify a potential approach for PD treatment.

arigo provides excellent antibodies and ELISA kits to facilitate PD research.

Detection of dopamine levels & DA neurons

Dopamine ELISA Kit (ARG80450)
Reactivity: Hu, Ms, Rat
Sample: Biological samples

Tyrosine Hydroxylase antibody (ARG52461)
Reactivity: Hu, Ms, Rat, Mamm
Application: ICC/IF, IHC-Fr, IHC-P, WB

Astrocyte-to-neuron conversion

Astrocyte Marker Antibody Duo (ARG30007)

Neurite Marker Antibody Duo (ARG30301)

PD research

PINK1 antibody (ARG55419)
Reactivity: Hu, Ms, Rat
Application: ICC/IF, IHC-P, WB

DJ-1 antibody (ARG58150)
Reactivity: Hu, Ms, Rat
Application: FACS, IHC-P, WB

Reference: Qian et al., (2020) Nature. 582(7813):550-556.